Regional and temporal heterogeneity of epithelial ovarian cancer tumor biopsies: implications for therapeutic strategies.
drug resistance
ovarian cancer
spatial heterogeneity
targeted next generation sequencing
temporal heterogeneity
Journal
Oncotarget
ISSN: 1949-2553
Titre abrégé: Oncotarget
Pays: United States
ID NLM: 101532965
Informations de publication
Date de publication:
23 Nov 2021
23 Nov 2021
Historique:
received:
01
03
2016
accepted:
23
05
2016
entrez:
2
12
2021
pubmed:
9
7
2016
medline:
9
7
2016
Statut:
epublish
Résumé
Stage III/IV epithelial ovarian cancer (EOC) is a systemic disease. The clonal relationship among different tumor lesions at diagnosis (spatial heterogeneity) and how tumor clonal architecture evolves over time (temporal heterogeneity) have not yet been defined. Such knowledge would help to develop new target-based strategies, as biomarkers which can adjudge the success of therapeutic intervention should be independent of spatial and temporal heterogeneity. The work described in this paper addresses spatial and temporal heterogeneity in a cohort of 71 tumor biopsies using targeted NGS technology. These samples were taken from twelve high grade serous (HGS) and seven non HSG-EOC, both at the time of primary surgery when the tumor was naïve to chemotherapy and after chemotherapy. Matched tumor lesions growing in the ovary or at other anatomical sites show very different mutational landscapes with branched tumor evolution. Mutations in
Identifiants
pubmed: 34853661
doi: 10.18632/oncotarget.10505
pii: 10505
pmc: PMC8629406
doi:
Types de publication
Journal Article
Langues
eng
Pagination
2404-2417Informations de copyright
Copyright: © 2021 Paracchini et al.
Déclaration de conflit d'intérêts
CONFLICTS OF INTEREST The authors have declared no conflicts of interest.
Références
Bioinformatics. 2009 Jul 15;25(14):1754-60
pubmed: 19451168
Ann Oncol. 2010 Oct;21 Suppl 7:vii218-22
pubmed: 20943618
Genome Res. 2014 Oct;24(10):1624-36
pubmed: 25030888
Nat Rev Cancer. 2009 Apr;9(4):302-12
pubmed: 19308069
Clin Cancer Res. 2014 Feb 1;20(3):764-75
pubmed: 24240112
Cancer Cell. 2003 Jul;4(1):4-6
pubmed: 12892707
Clin Cancer Res. 2009 Feb 15;15(4):1417-27
pubmed: 19193619
Nat Rev Cancer. 2011 Sep 23;11(10):719-25
pubmed: 21941283
J Pathol. 2013 Sep;231(1):21-34
pubmed: 23780408
Nature. 2013 Aug 22;500(7463):415-21
pubmed: 23945592
Ann Oncol. 2015 Jul;26(7):1363-71
pubmed: 25846551
Cancer Res. 2012 Oct 1;72(19):4875-82
pubmed: 23002210
Nat Biotechnol. 2013 Mar;31(3):213-9
pubmed: 23396013
Nature. 2011 Jun 29;474(7353):609-15
pubmed: 21720365
PLoS Med. 2015 Feb 24;12(2):e1001789
pubmed: 25710373
Genome Res. 2012 Mar;22(3):568-76
pubmed: 22300766
Genome Res. 2014 Feb;24(2):200-11
pubmed: 24221193